This is a promising biomarker to discriminate progressors from non-progressors and even has potential as a therapeutic target; antibodies to CD24 have been used in in in vitro and murine models to suppress invasion and proliferation of tumour cells through interruption of STAT3 phosphorylation (36), and Ras/BCL-2 pathway down-regulation (37, 38). This evidence concerns the gene BCL2 and neoplasm.